[1] 高佳星.早发型重度子痫前期发病机制及其期待疗法的研究进展[J].中外健康文摘,2012,2(9):449-450.
[2] LANGENVELD J,BUTTINGER A,van der POST J,et al.Recurrence risk and prediction of a delivery under 34 weeks of gestation after a history of a severe hypertensive disorder[J].BJOG,2011,118(5):589-595.
[3] CHESLEY L,COPPER D W.Genetics of hypertension in pregnancy:possible single gene control of preeclampsia and eclampsia in the descendants of eclamptic women[J].Br J Obstet Gynecol,1986,93(9):898-908.
[4] MASOURA S,KALOGIANNIDIS I A,GITAS G,et al.Biomarkers in preeclampsia:a novel approach to early detection of the disease[J].J Obstet Gynaecol,2012,32(7):609-616.
[5] SEKIZAWA A,PURWOSUNU Y,YOSHIMURA S,et al.PP13 mRNA expression in trophoblasts from preeclamptic placentas[J].Reprod Sci,2009,16(4):408-413.
[6] CHAFETZ I,KUHNREICH I,SAMMAR M,et al.First-trimester placental protein 13 screening for preeclampsia and intrauterine growth restriction[J].Am J Obstet Gynecol,2007,197(1):35.e1-7.
[7] ROMERO R,KUSANOVIC J P,THAN N G,et al.First-trimester maternal serum PP13 in the risk assessment for preeclampsia[J].Am J Obstet Gynecol,2008,199(2):122.e1-122.e11.
[8] COWANS N J,SPENCER K,MEIRI H.First-trimester maternal placental protein 13 levels in pregnancies resulting in adverse outcomes[J].Prenat Diagn,2008,28(2):121-125.
[9] STEINBERG G,KHANKIN E V,KARUMANCHI S A.Angiogenic factors and preeclampsia[J].Thromb Res,2009,123:S93-99.
[10] LI X,SHEN L,TAN H.Polymorphisms and plasma level of transforming growth factor-Beta 1 and risk for preeclampsia:a systematic review[J].PLoS One,2014,9(5):e97230.
[11] LYKKE J A,LANGHOFF-ROOS J,SIBAI B M.Hypertensive pregnancy disorders and subsequent cardiovascular morbidity and type 2 diabetes mellitus in the mother[J].Hypertension,2009,53(6):944-951.
[12] KIM Y K,LEE D S,JEONG D H,et al.The relationship of the level of circulating antiangiogenic factors to the clinical manifestations of preeclampsia[J].Prenat Diagn,2009,29(5):464-470.
[13] WIKSTROM A K,LARSSON A,AKERUD H,et al.Increased circulating levels of the antiangiogenic factor endostatin in early-onset but not late-onset preeclampsia[J].Reprod Sci,2009,16(10):995-1000.
[14] GAUSTER M,MOSER G,ORENDI K,et al.Factors involved in regulating trophoblast fusion:potential role in the development of preeclampsia[J].Placenta,2009,30:S49-54.
[15] de VIVO A,BAVIERA G,GIORDANO D,et al.Endoglin,PlGF and sFlt-1 as markers for predicting preeclampsia[J].Acta Obstet Gynecol Scand,2008,87(8):837-842.
[16] KUSANOVIC J P,ROMERO R,CHAIWORAPONGSA T,et al.A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia[J].J Matern Fetal Neonatal Med,2009,22(11):1021-1038.
[17] STEPAN H,GEIPEL A,SCHWARZ F,et al.Circulatory soluble endoglin and its predictive value for preeclampsia in second-trimester pregnancies with abnormal uterine perfusion[J].Am J Obstet Gynecol,2008,198(2):175.e1-6.
[18] 汤琳琳,徐友娣,薛鑫源.子痫前期患者血脂水平及脂蛋白脂酶基因多态性相关性研究[J].东南大学学报:医学版,2013,32(1):23-29.
[19] SPENCER K,COWANS N J,CHEFETZ I,et al.Second-trimester uterine artery Doppler pulsatility index and maternal serum PP13 as markers of preeclampsia[J].Prenat Diagn,2007,27:258-263.
[20] 杨孜,李蓉,石凌懿,等.早发型重度子痫前期的临床界定及保守治疗的探讨[J].中华妇产科杂志,2005,40(5):302-305.
[21] BAHADO-SINGH R O,AKOLEKAR R,MANDAL R,et al.Metabolomics and first-trimester prediction of early-onset preeclampsia[J].J Matern Fetal Neonatal Med,2012,25(10):1840-1847.
[22] CARADEUX J,SERRA R,NIEN J K,et al.First trimester prediction of early onset preeclampsia using demographic,clinical,and sonographic data:a cohort study[J].Prenatal Diagnosis,2013,33:732-736.
[23] POON L C,KAMETAS N A,MAIZ N,et al.First-trimester prediction of hypertensive disorders in pregnancy[J].Hypertension,2009,53(5):812-818.
[24] 李朝曦,苏放明.子痫前期预测的最新研究进展[J].现代医学,2012,40(1):118-121. |